Global Stem Cell Therapy Market to surpass $ 15 Bn by 2025

February 04, 2020


According to a recent study titled, ‘Stem Cell Therapy Market Size By Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Application (Oncology, Orthopedic, Cardiovascular, Neurology), End-users (Hospitals, Clinics) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Japan, China, India, Australia, South Korea, Argentina, Brazil, Mexico, South Africa, Saudi Arabia, UAE), Technology Potential, Competitive Market Share & Forecast, 2019 - 2025’, available with Market Study Report LLC, the global stem cell therapy market is expected to cross USD 15 billion by the year 2025.
 

Increasing R&D on novel therapies and personalized medicines for treating neurological and cardiovascular diseases is driving the growth of stem cell therapy market. For instance, scientists are extensively researching to regenerate healthy heart cells from placenta to be used in patients after a heart attack.
 

Rising geriatric population which is prone to degenerative diseases such as Parkinson’s and Alzheimer’s, is augmenting the stem cell therapy market size. Recent stem cell therapies are minimally invasive and offer several benefits as compared to conventional therapeutic methods, thereby, positively impacting the market outlook.
 

Based on the type, allogenic stem cell therapy market was worth USD 3 billion in 2018 and is expected to witness significant growth in the forthcoming years. Allogenic stem cell therapy entirely removes host cells and transplants donor cells in its place. Allogenic transplant can also eliminate viral reserves and genetic alterations. These benefits coupled with growing application in treating various fatal diseases is driving the growth of allogenic stem cell therapy market.
 

In terms of the application scope, stem cell market from orthopedic segment is anticipated to witness a growth rate of 9% during the predicted timeframe, on account of increasing accident and trauma cases with some form of bone-joint injuries associated with them. Stem cell therapy can successfully treat injuries such as spinal defect, bone fractures, femoral head, and osteogenesis imperfecta, and ligament tendon.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2100692/
 

Based on the end-users, the report cites that clinics segment registered a 35% revenue share in 2018 and is anticipated to grow considerably during the analysis period, owing to the superior benefits clinics provide. Specialized clinics have an advanced healthcare framework which enables skilled professionals to provide quality stem cell therapies. However, high treatment cost may hamper the segmental growth during the forecast period.
 

Considering the geographical outlook, Europe stem cell therapy market is slated to witness a growth of 10% between 2019-2025, due to the high prevalence of chronic diseases in the region. Moreover, implementation of favorable regulations coupled with growing awareness towards the benefits of stem cell therapy is enhancing the regional outlook.
 

Key players in the stem cell therapy market include Astellas Pharma, Celyad, Cellectis, ReNeuron Group, Capricor Therapeutics, Gamida Cell, Cellular Dynamics, CESCA Therapeutics, Novadip Biosciences, DiscGenics, Mesoblast, OxStem, and Takeda Pharmaceuticals.


Frequently Asked Questions (FAQ) :

Increasing R&D on novel therapies and personalized medicines for treating neurological and cardiovascular diseases is driving the growth of stem cell therapy market. For instance, extensive research to regenerate healthy heart cells from placenta to be used in patients after a heart attack. Rising geriatric population which is prone to degenerative diseases such as Parkinson’s and Alzheimer’s, is augmenting the stem cell therapy market size. Recent stem cell therapies are minimally invasive and offer several benefits as compared to conventional therapeutic methods, thereby, positively impacting the market outlook.
Allogenic stem cell therapy market was worth USD 3 billion in 2018 and is expected to witness significant growth in the forthcoming years. Allogenic stem cell therapy entirely removes host cells and transplants donor cells in its place. Allogenic transplant can also eliminate viral reserves and genetic alterations. These benefits coupled with growing application in treating various fatal diseases is driving the growth of allogenic stem cell therapy market.
Europe stem cell therapy market is slated to witness a growth of 10% between 2019-2025, due to the high prevalence of chronic diseases in the region. Moreover, implementation of favorable regulations coupled with growing awareness towards the benefits of stem cell therapy is enhancing the regional outlook.
Key players in the stem cell therapy market include Astellas Pharma, Celyad, Cellectis, ReNeuron Group, Capricor Therapeutics, Gamida Cell, Cellular Dynamics, CESCA Therapeutics, Novadip Biosciences, DiscGenics, Mesoblast, OxStem, and Takeda Pharmaceuticals.